BridgeBio Pharma, Inc.
BBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $222 | $9 | $78 | $70 |
| % Growth | 2,285.3% | -88% | 11.4% | – |
| Cost of Goods Sold | $4 | $2 | $3 | $3 |
| Gross Profit | $218 | $7 | $74 | $67 |
| % Margin | 98.3% | 73.7% | 95.6% | 95.5% |
| R&D Expenses | $506 | $456 | $399 | $451 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $289 | $151 | $143 | $192 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $16 | $8 | $44 | $0 |
| Operating Expenses | $811 | $614 | $586 | $643 |
| Operating Income | -$593 | -$607 | -$512 | -$577 |
| % Margin | -267.2% | -6,528.8% | -659.6% | -827.1% |
| Other Income/Exp. Net | $51 | -$46 | $28 | -$10 |
| Pre-Tax Income | -$542 | -$653 | -$485 | -$586 |
| Tax Expense | $1 | $0 | $0 | $0 |
| Net Income | -$536 | -$643 | -$481 | -$563 |
| % Margin | -241.4% | -6,913.9% | -619.7% | -806.9% |
| EPS | -2.88 | -3.95 | -3.35 | -4.43 |
| % Growth | 27.1% | -17.9% | 24.4% | – |
| EPS Diluted | -2.88 | -3.95 | -3.35 | -4.43 |
| Weighted Avg Shares Out | 186 | 163 | 147 | 144 |
| Weighted Avg Shares Out Dil | 186 | 163 | 147 | 144 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $18 | $8 | $1 |
| Interest Expense | $99 | $81 | $80 | $47 |
| Depreciation & Amortization | $6 | $6 | $7 | $6 |
| EBITDA | -$437 | -$565 | -$397 | -$534 |
| % Margin | -196.9% | -6,078.3% | -511.9% | -765.7% |